Medical Scientist Training Program, University of Illinois College of Medicine, Chicago, IL, USA.
Department of Surgery, University of Illinois at Chicago, IL, Chicago, USA.
BMC Cancer. 2022 Jun 24;22(1):697. doi: 10.1186/s12885-022-09742-7.
Anal squamous cell carcinoma (SCC) generally carries a favorable prognosis, as most tumors are highly sensitive to standard of care chemoradiation. However, outcomes are poor for the 20-30% of patients who are refractory to this approach, and many will require additional invasive procedures with no guarantee of disease resolution.
To identify the patients who are unlikely to respond to the current standard of care chemoradiation protocol, we explored a variety of objective clinical findings as a potential predictor of treatment failure and/or mortality in a single center retrospective study of 42 patients with anal SCC.
Patients with an increase in total peripheral white blood cells (WBC) and/or neutrophils (ANC) had comparatively poor clinical outcomes, with increased rates of death and treatment failure, respectively. Using pre-treatment biopsies from 27 patients, tumors with an inflamed, neutrophil dominant stroma also had poor therapeutic responses, as well as reduced overall and disease-specific survival. Following chemoradiation, we observed uniform reductions in nearly all peripheral blood leukocyte subtypes, and no association between peripheral white blood cells and/or neutrophils and clinical outcomes. Additionally, post-treatment biopsies were available from 13 patients. In post-treatment specimens, patients with an inflamed tumor stroma now demonstrated improved overall and disease-specific survival, particularly those with robust T-cell infiltration.
Combined, these results suggest that routinely performed leukocyte subtyping may have utility in risk stratifying patients for treatment failure in anal SCC. Specifically, pre-treatment patients with a high WBC, ANC, and/or a neutrophil-dense tumor stroma may be less likely to achieve complete response using the standard of care chemoradiation regimen, and may benefit from the addition of a subsequent line of therapy.
肛门鳞状细胞癌(SCC)的预后通常较好,因为大多数肿瘤对标准护理放化疗高度敏感。然而,对于 20-30%对这种方法有抗药性的患者来说,结果很差,许多患者将需要额外的侵入性手术,而且不能保证疾病得到解决。
为了确定那些不太可能对当前标准护理放化疗方案有反应的患者,我们在对 42 名肛门 SCC 患者的单中心回顾性研究中,探索了各种客观的临床发现,作为治疗失败和/或死亡的潜在预测因素。
外周血白细胞(WBC)和/或中性粒细胞(ANC)总数增加的患者临床结局较差,死亡率和治疗失败率分别升高。使用 27 名患者的治疗前活检,炎症性、中性粒细胞占主导地位的肿瘤基质也有较差的治疗反应,以及总生存率和疾病特异性生存率降低。在放化疗后,我们观察到几乎所有外周血白细胞亚型都均匀减少,外周血白细胞和/或中性粒细胞与临床结果之间没有关联。此外,13 名患者的治疗后活检可用。在治疗后的标本中,现在炎症性肿瘤基质的患者表现出更好的总生存率和疾病特异性生存率,特别是那些有强大 T 细胞浸润的患者。
综合这些结果表明,常规进行白细胞亚型分析可能有助于对肛门 SCC 患者进行治疗失败的风险分层。具体来说,治疗前白细胞计数、ANC 和/或中性粒细胞密度高的患者可能不太可能通过标准护理放化疗方案实现完全缓解,可能受益于后续的治疗方案。